Gogoro Inc vs GSK plc — how do they compare? Gogoro Inc trades at $3.86 (market cap $77.38M), while GSK plc trades at $52.61 (market cap $101.34B). The key difference: GSK plc is far larger — about 1309.6× Gogoro Inc's market cap, and GSK plc pays a 3.49% dividend while Gogoro Inc pays none. Which is the better fit depends on your goals.
| GGR | GSK | |
|---|---|---|
Market Cap | $77.38M | $101.34B |
Sector | Technology | Health |
52-Week High | $7.89 | $61.18 |
52-Week Low | $2.74 | $36.20 |
Enterprise Value | $379.83M | $121.95B |
Dividend Yield | — | 3.49% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
Trailing returns across standard periods
Latest headlines on both assets
Gogoro is a global technology leader in battery-swapping ecosystems for electric two-wheelers. It provides smart, sustainable urban mobility solutions and manages an extensive network of battery stations.
Read more on GGR →In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →